Out of frame peptides from BCR/ABL alternative splicing are immunogenic in HLA A2.1 transgenic mice

Cancer Letters

Volumn 276, Issue 1, 2009, Pages 61-67

  Casnici, C ^a   Volpe, G ^b   Lattuada, D ^a   Crotta, K ^a   Kuka, M ^b   Panuzzo, C ^b   Mastrotto, C ^a   Tonon, G ^c   Fazio, V M ^d,e   Saglio, G ^b   Marelli, O ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c Bio Ker ^*  (Italy)

^d UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^e CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

Author keywords

BCR ABL transcripts; Cancer vaccine; Chronic myelogenous leukemia; HLA A2.1 transgenic mice; Peptide vaccination

Indexed keywords

AMINO ACID; BCR ABL PROTEIN; CANCER VACCINE; HLA A2 ANTIGEN; HYBRID PROTEIN; PEPTIDE VACCINE; TUMOR ANTIGEN;

ACUTE LYMPHOCYTIC LEUKEMIA; ALTERNATIVE RNA SPLICING; AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; C57BL 6 MOUSE; CANCER IMMUNIZATION; CARBOXY TERMINAL SEQUENCE; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CYTOTOXIC LYMPHOCYTE; EXON; GENE IDENTIFICATION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOGENICITY; IN VIVO STUDY; LEUKEMIA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSGENIC MOUSE;

ALTERNATIVE SPLICING; AMINO ACID SEQUENCE; ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; CELL LINE, TUMOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; FRAMESHIFT MUTATION; FUSION PROTEINS, BCR-ABL; HLA-A2 ANTIGEN; HUMANS; INTERFERON-GAMMA; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MOLECULAR SEQUENCE DATA; PEPTIDES; PROTO-ONCOGENE PROTEINS C-BCR; T-LYMPHOCYTES, CYTOTOXIC;

MUS MUSCULUS;

EID: 60549094771     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2008.10.032     Document Type: Article

References (12)

1. Clark R.E., Dodi I.A., Hill S.C., Lill J.R., Aubert G., Macintyre A.R., Rojas J., Bourbon A., Bonner P.L.R., Wang L., Christmas S.E., and Travers P.J. Direct evidence that leukemic cells present HLA-associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein. Blood 98 (2001) 2887-2893
2. Bocchia M., Korontsvit T., Xu Q., Mackinnon S., Yang S.Y., Sette A., and Scheinberg D.A. Specific human cellular immunity to bcr-abl oncogene-derived peptides. Blood 87 (1996) 3587-3592
3. Norbury L.C., Clark R.E., and Christmas S.E. b3a2 BCR-ABL fusion peptides as targets for cytotoxic T cells in chronic myeloid leukaemia. Br. J. Hematol. 109 (2000) 616-621
4. Cathcart K., Pinilla-Ibarz J., Korontsvit T., Schwartz J., Zakhaleva V., Papadopoulos E.B., and Scheinberg D.A. A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia. Blood 103 (2004) 1037-1042
5. Bocchia M., Gentili S., Abruzzese E., Fanelli A., Iuliano F., Tabilio A., Amabile M., Forconi F., Gozzetti A., Raspadori D., Amadori S., and Lauria F. Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukemia and persistent residual disease: a multicentre observation trial. Lancet 3658 (2005) 657-662
6. Molldrem J.J., Lee P.P., Wang C., Champlin R.E., and Davis M.M. A PR1-human leukocyte antigen-A2 tetramer can be used to isolate low-frequency cytotoxic T lymphocytes from healthy donors that selectively lyse chronic myelogenous leukemia. Cancer Res. 59 (1999) 2675-2681
7. Grunebach F., Mirakaj V., Muller M.R., Brummendorf T., and Brossart P. Bcr-Abl is not an immunodominant antigen in chronic myelogenous leukemia. Cancer Res. 66 (2006) 5892-5900
8. Volpe G., Cignetti A., Panuzzo C., Kuka M., Vitaggio K., Brancaccio M., Perrone G., Rinaldi M., Prato G., Fava M., Geuna M., Pautasso M., et al. Alternative BCR/ABL splice variants in Philadelphia chromosome positive leukemias result in novel tumor specific fusion proteins that may represent potential targets for immunotherapic approaches. Cancer Res. 67 (2007) 5300-5307
9. Falini B., Mecucci C., Tiacci E., Alcalay M., Rosati R., Pasqualucci L., La Starza R., Diverio D., Colombo E., Cantucci A., Bigerna B., Pacini R., et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N. Engl. J. Med. 352 (2005) 254-266
10. Saeterdal I., Biorheim J., Lislerud K., Gjertsen M.K., Bukholm I.K., Olsen O.C., Nesland J.M., Eriksen J.A., Moller M., Lindblom A., and Gaudernack G. Frameshift-mutation-derived peptides as tumor-specific antigens in inherited and spontaneous colorectal cancer. Proc. Natl. Acad. Sci. USA 98 (2001) 13255-13260
11. Irwin M.J., Heath W.R., and Sherman L.A. Species-restricted interactions between CD8 and the α3 domain of class I influence the magnitude of the xenogenenic response. J. Exp. Med. 170 (1989) 1091-1101
12. + T lymphocytes in IFN-gamma ELISPOT assays. J. Immunol. Methods 259 (2002) 95-110